Also known as
Other names:
- Body Protective Compound 157
- Bepecin
- PLD-116
- PL-10
- PL14736
- Wolverine drug
Therapeutic Goods Administration (TGA) approval
BPC-157 is not listed on the Australian Registered of Therapeutic Goods (ARTG).
World Anti-Doping Code Prohibited List 2025
BPC-157 is a prohibited substance listed under section S0 Non-Approved Substances.
S0 Non-Approved Substances are prohibited at all times and are Specified Substances.
|
Check medications, find batch-tested supplements and more:
Download the Sport Integrity App
|
The Prohibited List is updated yearly after consultation with scientific, medical, and anti-doping experts to ensure that it aligns with the latest medical and scientific evidence and doping trends.
What is it?
BPC-157 is an experimental peptide that is not approved for use by any regulatory agency worldwide.
It is prohibited by the World Anti-Doping Agency (WADA) and is listed on the WADA Prohibited List under S0 Non-Approved Substances.
These substances are banned at all times.
How does it work?
BPC-157 affects multiple biological pathways in the human body, which increase the formation of blood vessels and stimulates the growth of various tissues including muscle, bones, tendons and ligaments.
Uses
BPC-157 is not approved for human use.
There have been multiple preclinical studies investigating its potential to treat various conditions such as inflammatory bowel disease and soft tissue injuries.
None of these studies were conducted in humans.
It is marketed online as an anti-aging compound and a treatment to enhance recovery from musculoskeletal injuries.
Adverse health effects and risk
There are currently no studies investigating BPC-157’s use in human subjects.
The safety of both its short-term and long-term intake is unknown.
Some of the biological pathways and resulting byproducts associated with the use of BPC-157,
have been linked with:
- growth of tumours in humans
- cardiovascular disease and;
- multiple neurogenerative diseases, including:
- dementia
- Alzheimer’s and;
- Parkinson’s disease.
What if an athlete has been prescribed BPC-157 for a medical condition?
A Therapeutic Use Exemption (TUE) would not be granted for the use of BPC-157 in any medical condition.
References
- Australian Register of Therapeutic Goods (ARTG). [online] Therapeutic Goods Administration (TGA)
Available at: https://www.tga.gov.au/resources/artg [Accessed 13 Oct. 2025] - WADA (2025). The Prohibited List. [online] World Anti-Doping Agency
Available at: https://www.wada-ama.org/en/prohibited-list - McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine. 2025 Aug 12:1-9
- Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals. 2025 Jan 30;18(2):185
- Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal®. 2025 Nov;21(4):485-95